The Annual Economic Burden of RSV in Adults in the US, Recombinant or Standard-Dose Influenza Vaccine in Adults Under 65 Years of Age, and Optimal Timing of Nirmatrelvir/Ritonavir Treatment After COVID-19 Symptom Onset or Diagnosis

0 views
January 2, 2024
Comments 0
Login to view comments. Click here to Login